Li Zhao

Prof. Dr. Li Zhao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2016 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
LLLu Lu
Lu Lu
QGQinglong Guo
Qinglong Guo
LZLi Zhao
Li Zhao

1 April 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
XWXiaoping Wang
Xiaoping Wang
YSYang Sun
Yang Sun
YZYue Zhao
Yue Zhao
YDYouxiang Ding
Youxiang Ding
XZXiaobo Zhang
Xiaobo Zhang
LZLi Zhao
Li Zhao

1 November 2018 in Chinese Journal of Natural Medicines
Verified
Journal Article
Closed access
YZYu Zhou
Yu Zhou
HCHan-Bo Cao
Han-Bo Cao
WLWen-Jun Li
Wen-Jun Li
LZLi Zhao
Li Zhao

15 October 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
YDYouxiang Ding
Youxiang Ding
KHKun Hao
Kun Hao
ZLZhaohe Li
Zhaohe Li
RMRong Ma
Rong Ma
YZYou Zhou
You Zhou
LZLi Zhao
Li Zhao

25 September 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
YLYunyao Liu
Yunyao Liu
XWXiaoping Wang
Xiaoping Wang
WLWenshu Li
Wenshu Li
YXYujiao Xu
Yujiao Xu
YZYating Zhuo
Yating Zhuo
LQLei Qiang
Lei Qiang

17 January 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YGYanping Gui
Yanping Gui
XQXiaoping Qian
Xiaoping Qian
YDYouxiang Ding
Youxiang Ding
QCQianqian Chen
Qianqian Chen
YYYuting Ye
Yuting Ye
LZLi Zhao
Li Zhao
Acquired drug resistance is one of the most common limitations for the clinical response of colon cancer to 5-Fluorouracil (5-FU)-based chemotherapy. The relevant molecular mechanisms might be diversity, but still not be elucidated clearly. In this study, we aimed to investigate the potential mechanisms of c-Fos, a subfamily of activator protein-1, in 5-FU chemoresistance. We determined that phosphorylated c-Fos promoted colon cancer cells resistance to 5-FU by facilitating the cancer stemness. Mechanically, 5-FU treatment induced autolysosome-dependent degradation of TMPO, which subsequently triggered ERK-mediated phosphorylation of c-Fos. Additionally, c-Fos was found to bind to the promoter of NANOG and phosphorylation of c-Fos at Ser 374 was required for its regulation of NANOG expression. NANOG ablation impaired c-Fos/p-c-Fos induced 5-FU resistance and stemness. Taken together, these findings revealed that TMPO-mediated phosphorylation of c-Fos conferred 5-FU resistance by regulating NANOG expression and promoting cell stemness in colon cancer cells. c-Fos could be as a therapeutic target for colon cancer.